Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms 1 Metastatic Urothelial Cell Cancer 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 HER-2 Positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma 1

Interventions

Rituximab 66 Cyclophosphamide 52 fludarabine phosphate 26 fludarabine 22 Filgrastim 21 Vincristine 19 Methotrexate 19 Melphalan 19 Doxorubicin 18 Radiotherapy 17 Etoposide 17 Prednisone 16 Tacrolimus 15 Whole-Body Irradiation 14 Mycophenolic Acid 14 Cytarabine 14 Peripheral Blood Stem Cell Transplantation 13 Gemcitabine 13 Cyclosporine 13 Antilymphocyte Serum 13 Lenalidomide 12 Busulfan 11 Bortezomib 11 Granulocyte Colony-Stimulating Factor 9 Alemtuzumab 9 sargramostim 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 pembrolizumab 7 ibritumomab tiuxetan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × eribulin × Clear all

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡